natgillin/translations-raw huggingface dataset:
Aktivna patološka krvavitev kot je peptična razjeda ali 
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.
nesteroidna protivnetna zdravila (za lajšanje bolečin zaradi vnetih sklepov ali mišic). 
• Non-steroidal anti-inflammatory medicines (used to treat painful inflammatory conditions of the joints or muscles).
Bolnike je treba ocenite glede na anamnezo preobčutljivosti na tienopiridine (na primer na klopidogrel, tiklopidin in prasugrel), ker so poročali o navzkrižnih alergijah med tienopiridini (glejte poglavje 4.8). 
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8).
Ta korist se je pokazala v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni 
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group].
Priporočeni odmerek acetilsalicilne kisline je bil od 75 do 100 mg na dan. 
The recommended dose for ASA was 75 to 100 mg/day.
Okvarjeno delovanje ledvic Terapevtske izkušnje pri bolnikih z okvaro ledvic so omejene (glejte poglavje 4.4). 
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4).
Bolezni imunskega sistema serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)* 
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
Pri manjših urezninah ali poškodbah (npr. če se urežete pri britju), to navadno ni zaskrbljujoče. 
For minor cuts and injuries (e.g. shaving cuts) you should not worry.
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišano vrednost srčnih encimov ali 
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
V majhnem številu primerov so poročali tudi o očesnih krvavitvah, krvavitvah v glavi, pljučih ali sklepih. 
In a small number of cases, bleeding in the eye, inside the head, the abdomen, the lung and the joints have also been reported.
simptomov in z njim nadaljevati vsaj štiri tedne. 
Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks.
Sočasna uporaba heparina ni imela nobenega vpliva na zaviranje agregacije trombocitov, sproženo 
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.
selektivne zaviralce privzema serotonina (vključno a ne omejeno na fluoksetin ali fluvoksamin), 
• a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
Nadaljnja presnova vmesnega presnovka 2oksoklopidogrela povzroči nastanek aktivnega presnovka, ki je tiolski derivat klopidogrela. 
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.
Zaradi previdnosti se je treba izogniti sočasni uporabi omeprazola ali esomeprazola (glejte poglavje 4.4). 
As a precaution, concomitant use of omeprazole or esomeprozole should be discouraged (see section 4.4).
14x1 filmsko obložena tableta 28x1 filmsko obložena tableta 30x1 filmsko obložena tableta 50x1 filmsko obložena tableta 84x1 filmsko obložena tableta 90x1 filmsko obložena tableta 100x1 filmsko obložena tableta peroralna uporaba Pred uporabo preberite priloženo navodilo. 
14x1 film-coated tablet 28x1 film-coated tablet 30x1 film-coated tablet 50x1 film-coated tablet 84x1 film-coated tablet 90x1 film-coated tablet 100x1 film-coated tablet
so preučevali v številnih študijah genotoksičnosti in vitro in in vivo, ki niso pokazale nobenega genotoksičnega učinka. 
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity.
s hudo nevtropenijo trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija 
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Vrsta ovojnine in vsebina 
PHARMACEUTICAL FORM AND CONTENTS
Zato je pri sočasni uporabi potrebna previdnost (glejte poglavje 4.4). 
Therefore, concomitant use should be undertaken with caution (see section 4.4).
Posvetujte se tudi, če opazite katere koli neželene učinke, ki niso navedni v tem navodilu. 
This includes any possible side effects not listed in this leaflet.
Iz previdnosti naj sočasno ne bi uporabljali močnih ali srednje močnih zaviralcev CYP2C19 (glejte poglavji 4.4 in 5.2). 
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).
s CYP2C19, se razlikuje glede na raso/etnično pripadnost (glejte Farmakogenetika). 
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics).
Antidot farmakološkemu delovanju klopidogrela ni znan. 
No antidote to the pharmacological activity of clopidogrel has been found.
Kaj morate vedeti preden boste vzeli zdravilo Klopidogrel Teva Pharma B.V. 
What you need to know before you take Clopidogrel Teva Pharma B.V.
Če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih 
• You have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days
Opazovalne in klinične študije so dale razhajajoče se podatke o kliničnih posledicah tega farmakokinetičnega/farmakodinamskega medsebojnega delovanja, kar zadeva večje kardiovaskularne dogodke. 
Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim. 
even if their signs of illness are the same as yours.
Redno posodobljena poročila o varnosti zdravila (PSUR) 
Periodic Safety Update Reports
V razvrstitvah pogostnosti so neželeni učinki navedeni po organskih sistemih in po padajoči resnosti. 
Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness.
s klopidogrelom ali acetilsalicilno kislino, celokupna incidenca kakršnihkoli krvavitev 9,3 %. 
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
in strojev Malo verjetno je, da bi zdravilo Klopidogrel Teva Pharma B.V. vplivalo na vašo sposobnost upravljanja vozil 
Driving and using machines Clopidogrel Teva Pharma B.V. is unlikely to affect your ability to drive or operate machinery.
Imetnik dovoljenja za promet z zdravilom: 
Marketing Authorisation Holder:
Zato je potrebno pri teh bolnikih klopidogrel uporabljati previdno (glejte poglavje 4.2). 
Therefore clopidogrel should be used with caution in these patients (see section 4.2).
Pri analizi po načelu začetnega namena zdravljenja so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala acetilsalicilno kislino, 1.020 dogodkov (zmanjšanje relativnega tveganja (zmanjšanje RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, pri dodatnih 10 [IZ: 0 do 20] bolnikih. 
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
sočasna uporaba klopidogrela in peroralnih antikoagulansov ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4). 
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (obolenje krvnih žil z izjemo 
• You have hardening of the arteries and have recently suffered from a heart attack, a stroke or have a condition known as “peripheral arterial disease” (diseases of the blood vessels except those in the brain and heart).
To lahko pomeni, da je pri vas prisotna trombotična trombocitopenična purpura (redka motnja strjevanja krvi, ki lahko povzroči pojav številnih krvnih strdkov po celem telesu). 
This could indicate that you are suffering from a serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body)
Zdravila Klopidogrel Teva Pharma B.V. ne smete prenehati jemati, ne da bi se o tem prej posvetovali z zdravnikom. 
If you stop taking Clopidogrel Teva Pharma B.V. Do not stop taking Clopidogrel Teva Pharma B.V. without discussing it with your doctor first.
Drugi aleli, povezani z odsotno ali zmanjšano presnovo, so redkejši in vključujejo CYP2C19*4, *5, *6, *7 in *8. Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj. 
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8.
takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih, če krvavitve postanejo resne ali se pojavijo krvavitve na neobičajnih mestih telesa (glejte poglavje 2 »Opozorila in previdnostni ukrepi«). 
However, if you are in any doubt, bleeding becomes serious or you experience unexpected bleeding from unusual parts of your body you should contact your doctor straight away (see section 2 ‘Warnings and precautions').
Iz previdnostnih razlogov naj se z dojenjem med zdravljenjem z zdravilom Klopidogrel Teva Pharma B.V. ne nadaljuje. 
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Pharma B.V.
Bolnike je treba obvestiti, da je ob jemanju klopidogrela (samega ali v kombinaciji z acetilsalicilno kislino) čas, potreben za zaustavitev krvavitve, lahko daljši kot običajno, in da morajo 
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.
Oddvojite posamezno enoto pretisnega omota od preostalega traku z nežnim 
Separate one individual blister cell from the rest of the strip by gently tearing along the perforations around it.
Odrasli in starostniki Klopidogrel je treba dajati kot enkratni dnevni odmerek 75 mg. 
Clopidogrel should be given as a single daily dose of 75 mg.
Pokazala je, da se je v primerjavi z dobrimi metabolizatorji izpostavljenost aktivnemu presnovku pri srednjih metabolizatorjih za 28 % zmanjšala, pri slabih metabolizatorjih se je zmanjšala za 72 %, zavrtje agregacije trombocitov (5 µM ADP) pa se je zmanjšalo tako, da je bila razlika IPA v primerjavi z dobrimi metabolizatorji pri prvih 5,9 % in pri drugih 21,4 %. 
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki bromida). 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide).
s COX-2 inhibitorji, in klopidogrel sočasno uporabljati previdno (glejte poglavje 4.4). 
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Če bolnik izpusti odmerek: - če je zamuda manj kot 12 ur po pravem času: bolnik naj odmerek vzame takoj, potem pa 
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.
Bolezni jeter, žolčnika in žolčevodov akutna odpoved jeter, hepatitis, nenormalni testi jetrne funkcije 
Acute liver failure, hepatitis, abnormal liver function test
Če opazite kateri koli neželeni učinek, se posvetujete z zdravnikom ali farmacevtom. 
If you get any side effects, talk to your doctor or pharmacist.
Bolezni mišičnoskeletnega sistema in vezivnega tkiva mišično-skeletne krvavitve (hemartroza), artritis, artralgija, mialgija 
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Na voljo so testi za določitev bolnikovega CYP2C19-genotipa. 
Tests are available to determine a patient's CYP2C19 genotype.
Bolnike so spremljali 30 dni. Primarni opazovani dogodki so bili navzočnost kompozita zaradi infarkta zamašene arterije na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo. 
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography.
Bolniki so bili naključno razporejeni v skupino, ki je prejemala klopidogrel (udarni odmerek 300 mg, nato 75 mg/dan, n=6.259) ali skupino, ki je prejemala placebo (n=6.303), oboje prejeto v kombinaciji z acetilsalicilnsko kislino (75-325 mg enkrat na dan) in drugimi standardnimi terapijami. 
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije. 
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Če imate aterosklerozo (otrdele krvne žile), je pri vas prisotno povečano tveganje za nastanek krvnega strdka v krvnih žilah večje. 
If you suffer from hardening of the arteries (“atherosclerosis”) there is an increased risk of a blood clot forming in your blood vessels.
Po odmerni shemi 300 mg/75 mg se je antiagregacijski odziv pri slabih metabolizatorjih zmanjšal: povprečno IPA (5 µM ADP) je bilo 24 % (24 ur) in 37 % (5. 
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Na voljo so testi za ugotavljanje bolnikovega CYP2C19-genotipa. 
Tests are available to identify a patient's CYP2C19 genotype.
s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Opozorila in previdnostni ukrepi«). 
• Signs of liver problems such as yellowing of the skin and whites of the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions')
Zdravilo Klopidogrel Teva Pharma B.V. jemljejo odrasali za preprečavanje nastanka krvnih strdkov (trombov) ter tako preprečuje pojav resnih dogodkov, kot je srčni napad in kap. 
In adults Clopidogrel Teva Pharma B.V. reduces the risk of blood clots forming which in turn reduces the risk of serious conditions such as heart attack and stroke from occurring.
tablete in ovojnino, da bodo vedeli katere tablete ste zaužili. 
Please take this leaflet, any remaining tablets and the container with you to the hospital or doctor so that they know which tablets were consumed.
Bolnike z znano alergijo na tienopiridine je priporočljivo kontrolirati glede znakov preobčutljivosti. 
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised.
Bolezni dihal, prsnega koša in mediastinalnega prostora krvavitve v dihalih (hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis, eozinofilna pljučnica 
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
Klopidogrel je pomembno zmanjšal relativno tveganje za smrt zaradi kateregakoli vzroka za 7 % (p=0,029) in relativno tveganje za ponovni infarkt, kap ali smrt za 9 % (p=0,002), kar je predstavljalo absolutno zmanjšanje za 0,5 % oziroma 0,9 %. Ta koristni učinek se je pojavil pri vseh starostih, obeh spolih in ob jemanju fibrinolitikov ali brez njega, opažen pa je bil že po 24 urah. 
Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002), representing an absolute reduction of 0.5% and 0.9%, respectively.
acetilsalicilna kislina ni spremenila s klopidogrelom doseženega zaviranja agregacije trombocitov, ki je bila sprožena z ADP-jem, vendar je klopidogrel okrepil učinek acetilsalicilne kisline na s kolagenom 
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
povišana telesna temperatura, znaki okužbe (npr. vnetje grla), bledost kože ali huda utrujenost. 
• Fever, signs of infection (e.g. sore throat), pale skin or extreme tiredness.
Posebne skupine bolnikov Farmakokinetika aktivnega presnovka klopidogrela v teh posebnih 
The pharmacokinetics of the active metabolite of clopidogrel is not known in these special populations.
s hudo ledvično boleznijo (očistek kreatinina 5 do 15 ml/min) inhibicija z ADP sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah. 
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Če pri vas obstaja povečano tveganje za pojav krvavitev. 
• You are at increased risk of bleeding.
s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom 
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Pri ljudeh, ki so prejemali terapevtski odmerek klopidogrela, niso opazili nobenega učinka na jetrne presnovne encime. 
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.
s farmacevtom, preden vzamete katerokoli zdravilo. 
Ask your doctor or pharmacist for advice before taking any medicine.
morate zdravniku takoj povedati, če se pri vas pojavi bolezensko stanje (znano kot tombotična trombocitopenična purpura), ki vključuje spremembe vedenja, glavobol, komo, motnje vida, napade (krče), odpovedovanje ledvic, povišano telesno temperaturo, šibkost in krvavitev v trebuhu, črevesju ali na koži (vključno z drobnimi rdečimi pikami in večjimi odrgninami) (glejte 
• You should also tell your doctor immediately if you develop a medical condition (known as Thrombotic Thrombocytopenic Purpura) that includes altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas) (see section 4 ‘Possible Side Effects')
Pomožne snovi v jedru tablete so (glejte poglavje 2 »Zdravilo Klopidogrel Teva Pharma B.V. vsebuje laktozo« in »Zdravilo Klopidogrel Teva Pharma B.V. vsebuje hidrogenirano ricinusovo olje«: laktoza monohidrat, mikrokristalna celuloza, hidroksipropil celuloza (E463), krospovidon (tip A), hidrogenirano ricinusovo olje in natrijev lavrilsulfat. 
The other ingredients in the tablet core are (see section 2 ‘Clopidogrel Teva Pharma B.V. contains lactose' and ‘Clopidogrel Teva Pharma B.V. contains hydrogenated castor oil') lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose (E463), crospovidone (type A), hydrogenated castor oil and sodium laurilsulfate, and in the film-coating are lactose monohydrate, hypromellose (E464), titanium dioxide (E171), macrogol 4000, iron oxide red (E172), iron oxide yellow (E172), indigo carmine aluminium lake (E132).
Bolniki so 28 dni oziroma do odpusta dobivali klopidogrel (75 mg na dan, n=22.961) ali placebo (n=22.891) v kombinaciji z acetilsalicilnsko kislino (162 mg na dan). 
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge.
Vpliv CYP2C19-genotipa na klinične izide pri bolnikih, zdravljenih 
The influence of CYP2C19 genotype on clinical outcomes in patients treated with clopidogrel has not been evaluated in prospective, randomised, controlled trials.
Previdno odlepite zadnjo stran. 
- Keep this leaflet.
in esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, ciprofloksacin, cimetidin, karbamazepin, okskarbazepin in kloramfenikol. 
Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol.
Simptomi lahko vključujejo spremembe vedenja, glavobole, komo, motnje vida, napade (krče), odpovedovanje ledvic, povišano telesno temperaturo, hudo utrujenost, šibkost ali krvavitve iz želodca, črevesja ali kože (vključno z manjšimi rdečimi madeži ali večjimi odrgninami). 
Symptoms may include altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness, or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas)
Perforirani pretisni omoti iz aluminija za enkratno odmerjanje, ki se odlepijo in perforirani pretisni omoti za enkratno odmerjanje iz aluminija ter HDPE stekleničke z zaporkami iz polipropilena ter silikagel sušilno sredstvo. 
Aluminium-aluminium peelable perforated unit-dose blisters, aluminium-aluminium perforated unit dose blisters and HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant.
Krvavitve so bile najpogosteje opisan učinek tako v kliničnih študijah kot v obdobju 
Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment.
s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki se zdravijo z acetilsalicilno kislino, heparinom ali zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAID) vključno z zaviralci COX-2 ali 
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs).
tablete v obliki kapsul, ki imajo na eni strani gladko površino, na drugi strani pa vtisnjeno oznako »C75«. 
Light pink to pink, capsule-shaped film-coated tablets debossed with “C75” on one side and plain on the other side.